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Bacterial resistance to known therapeutics has led to
an urgent need for new chemical classes of antibac-
terial agents. To address this we have applied a
Staphylococcus aureus fitness test strategy to
natural products screening. Here we report the
discovery of kibdelomycin, a novel class of antibi-
otics produced by a new member of the genus
Kibdelosporangium. Kibdelomycin exhibits broad-
spectrum, gram-positive antibacterial activity and is
a potent inhibitor of DNA synthesis. We demonstrate
through chemical genetic fitness test profiling and
biochemical enzyme assays that kibdelomycin is
a structurally new class of bacterial type II topoiso-
merase inhibitor preferentially inhibiting the ATPase
activity of DNA gyrase and topoisomerase IV. Kibde-
lomycin is thus the first truly novel bacterial type II
topoisomerase inhibitor with potent antibacterial
activity discovered from natural product sources in
more than six decades.
INTRODUCTION
Bacterial strains continue to acquire resistance to clinically used
antibiotics with alarming frequency and pose a serious threat to
human lives (Klevens et al., 2007). According to a recent report,
methicillin-resistant Staphylococcus aureus (MRSA) infections
alone are responsible for about 18,000 deaths per year in the
United States (Klevens et al., 2007). Chemical modifications of
the natural product antibiotic lead structures, discovered more
than five decades ago, led to incrementally improved antibiotics
that continue to serve well and provide the current reservoir
of clinical antibiotics (Singh and Barrett, 2006). Regrettably,Chemistry & Biology 18, 95additional such improvements on existing chemical scaffolds
are proving challenging and can be only overcome by discovery
of new antibiotic scaffolds with either known or novel modes of
action that could be developed as effective treatment options
against drug-resistant bacteria. Most antibacterial leads are
derived from nature and we believe that nature will continue to
serve as a prolific source of new antibacterial leads. However,
it is now well documented that one of the biggest challenges in
natural products discovery remains the rediscovery of known
compounds. The probability of success for the discovery of
novel natural product antibiotics can be significantly improved
when fundamentally new screening technologies are coupled
with new producing sources of natural products. We have
made inroads to address both of these problems. First, we
have introduced a target-based, whole cell screening approach
that uses inducible antisense to down-regulate the expression of
individual essential gene targets in S. aureus, thereby sensitizing
the cells to inhibitors of those targets and enriching the pool of
screening hits for inhibitors specific to those targets or pathways
at the crude extract stage (Singh et al., 2007). Second, we have
expanded our efforts to isolate microorganisms from different
geographical regions and habitats (including marine microbes)
in combination with improved high-throughput fermentation
methods (Bills et al., 2008; Genilloud et al., 2011). The combina-
tion of these two approaches resulted in the discovery of platen-
simycin and platencin by using fabH/fabF antisense sensitized
strains (Jayasuriya et al., 2007; Kodali et al., 2005; Ondeyka
et al., 2006; Singh et al., 2006a; Wang et al., 2006, 2007; Young
et al., 2006) and a number of other novel natural products by
using a rpsD sensitized antisense strain (Ondeyka et al., 2007;
Singh et al., 2006b, 2008, 2009; Zhang et al., 2009a, 2009b).
The single strain S. aureus antisense-based screening ap-
proach was recently extended to a genome-wide fitness test
assay, its usewas validated bymechanistically profiling a diverse
set of 59 antibacterials (Donald et al., 2009), and it was applied to
the screening of a chemical collection, leading to the discovery
of a new class of cell wall inhibitors (Huber et al., 2009). The5–965, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 955
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RNA strains engineered for reduced expression of genes essen-
tial for cell growth. Reduced expression of target genes leads to
differential growth sensitivity of cells to compounds that either
inhibit the targeted gene product or related functions. When
combined into pools and grown together for approximately 20
population doublings in the presence of test compounds, these
differences in growth lead to specific antisense strains either
being depleted or enriched in the treated population. Using
multiplex polymerase chain reaction (PCR), capillary electropho-
resis and gene fragment analysis to compare the abundances of
the strains at the end of the experiment with mock-treated
controls generates characteristic antisense-induced strain
sensitivity (AISS) profiles that are indicative of a compound’s
whole-cell mechanism of action (MOA). Compound MOA can
either be inferred directly from the AISS profile or by comparison
with a database of AISS profiles of known inhibitors (Donald
et al., 2009). Both approaches are very useful for the discovery
and differentiation of new compounds by not only indicating
preliminary mechanistic information but also providing compar-
ative information that is of great value in de-replicating natural
products.
In a similar way as theCandida albicans fitness test assay was
applied for the discoveries of parnafungin (Jiang et al., 2008;
Parish et al., 2008) and other novel natural products as antifungal
agents (Herath et al., 2009; Ondeyka et al., 2009; Xu et al., 2007),
AISS profiling was used in antibacterial discovery to prioritize
extracts for natural products chemistry based on whether their
activities are likely working through either interesting known or
novel MOAs. Those compounds exhibiting a novel AISS profile
and likely containing chemical inhibitors not seen before in the
assay can be assigned to isolation chemistry. Screening of
natural products extracts and AISS profiling led to identification
of one such prioritized extract that exhibited an AISS profile with
a potentially novel MOA and led to the discovery of coelomycin
(Goetz et al., 2010).
Extracts producing AISS profiles that are similar to profiles
produced by known drugs with attractive target-based MOAs
may contain those known compounds, novel analogs of those
compounds, or potentially new structural classes of inhibitors
working through established drug targets. Extracts exhibiting
a known AISS profile can be analyzed further by high-resolution
mass spectrometry and other analytical techniques to either
confirm or rule out the presence of known inhibitors before any
isolation chemistry steps are undertaken. Continued screening
efforts led to the identification of a number of extracts exhibiting
known AISS profiles. Here we disclose the discovery of kibdelo-
mycin from Kibdelosporangium sp. (MA7385), a new class of
natural product bacterial type II topoisomerase inhibitor with
potent activity against both DNA gyrase and topoisomerase IV
(topoIV). This inhibitor showed broad-spectrum activity against
a range of important gram-positive bacteria without cross-resis-
tance to known gyrase inhibitors.
RESULTS
S. aureus Fitness Test Screening of Crude Extracts
We set up a program to systematically screen crude natural
product extracts through the S. aureus fitness test to discover956 Chemistry & Biology 18, 955–965, August 26, 2011 ª2011 Elsevinew antibacterial agents working through target-based MOAs.
At the front end of this program, new bacterial and fungal isolates
were acquired from around the world, grown under 8–12
different culture conditions, and extracted with acetone, and
crude extracts were screened for antibacterial activity against
S. aureus. Extracts exhibiting S. aureus activity were then
subjected to the S. aureus fitness test for AISS profiling
(Donald et al., 2009) for MOA determination and prioritization
for natural products chemistry. One such extract derived
from a Kibdelosporangium strain, isolated from a soil sample
collected in a forest in the Central African Republic, generated
AISS profiles that were highly correlated to those generated in
the S. aureus fitness test for the natural product coumarin antibi-
otic novobiocin (Figure 1). AISS profiles for the coumarin antibi-
otic novobiocin are characterized by strong depletions in the
parE and parC-antisense (AS) strains (the two subunits of topoIV)
and the gyrB-AS and gyrA-AS strains (the two subunits of DNA
gyrase) (Donald et al., 2009). The crude extract shows strong
depletions in parE/C-AS and gyrB-AS and weak depletions of
gyrA-AS along with subtle differences in other strains (Figure 1).
These fitness test results were predictive of the extract con-
taining a known coumarin antibiotic, a new coumarin analog,
or a new structural class working through a similar MOA to novo-
biocin. Up to this point the program had already identified
a number of examples of extracts containing the coumarin
antibiotics novobiocin, chlorobiocin, and coumermycin A1 (not
shown). Because high-resolution electrospray ionization Fourier
transform mass spectral analysis (HRESIFTMS) was unable to
identify coumarin antibiotics in the crude extract (data not
shown), this extract was prioritized for natural products chem-
istry to isolate the active component responsible for the
coumarin-like AISS profile.
Isolation and Structure Elucidation
The producing organism, Kibdelosporangium sp., MA7385, was
grown in a liquid culture for 7 days and broth was extracted with
equal volume of acetone. Kibdelomycin was purified from the
extract by successive steps of extractions, normal phase (silica
gel), and reversed-phase chromatographies. Kibdelomycin (Fig-
ure 2) showed a molecular weight of 938 and molecular formula
of C44H60Cl2N4O14 by HRESIFTMS. This formula was supported
by the observation of the corresponding number of 13C shifts in
the 13C NMR spectrum in methanol-d4 (Table 1; see Figure S1
available online) and 1H shifts in the 1H NMR spectrum (Table
1; Figure S2). The structure of kibdelomycin was elucidated by
application of two-dimensional NMR techniques (COSY,
HMQC, HMBC, and ROESY) in a number of deuterated solvents
(methanol-d4, pyridine-d5, and DMSO-d6) but only data in metha-
nol-d4 is shown here. The COSY spectrum showed
1H-1H cross
peaks that allowed connectivities and establishment of frag-
ments C1-(C20)-C10-C21, C-14-C-17-(C18-C19), C22-C28,
C30-C33, C33-C34, and C37-C38. These fragments were con-
nected to establish a planar structure by analysis of HMBC
correlations and data is summarized in Table 1. The relative
configuration of kibdelomycin was elucidated by ROESY corre-
lations (Table 1). H-4 showed two key ROESY correlations: one
with H-10 as a result of a 1,3-diaxial relationship and the other
with H-30 as a result of a proximal facial relationship. Further
ROESY correlations of H-30 with H-34, H-31ax with H-33 ander Ltd All rights reserved
Figure 1. Two-Dimensional Cluster Analysis of S. aureus Fitness Test Profiles for the Crude Extract, Kibdelomycin, and Four Compounds of
Known Mechanism of Action
Strain depletions are depicted in magenta, strain resistances in cyan. The thresholds for including strains in the cluster analysis are >5-fold depletion, p-value%
0.01 in at least 4 of the experiments for any one compound or extract. The compound name is followed by the treatment concentration. Profiles for the Crude
Extract and Kibdelomycin cluster tightly with profiles of the antibiotic Novobiocin. The antisense strains targeting the 2 subunits of DNA gyrase (gyrA, gyrB) and
DNA topoisomerase IV (parC, parE) are shown in red.
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Discovery of KibdelomycinH-37, H-5 with H-9, and H-10 with CH3-21 helped elucidate the
configuration of C1-C10 and C4-C30-C38. The relative configu-
ration of the remainder of the molecule was independently
established by ROESY correlations of H-17 with H-22, and
H-22 to CH3-28, H-23, and H-25. The four structural motifs of
kibdelomycin were connected with each other with hetero atoms
and confirmed by HMBC. The central 4-hydroxy decalin tetramic
acid core is tethered on one side to a novel 6-methyl-2-methoxy-
3-acetoxy-4-carbamoyl-epiallose residue (Sugar A) by an
N-glycosidic linkage to tetramic acid and on the other side to
3-a-aminoethyl-3,6-dideoxy hexopyranose (Sugar B) by anChemistry & Biology 18, 95O-glycosidic linkage. The amino group of the amino ethyl sub-
stitution of the sugar B forms an amide bond with 3,4-dichloro-
5-methyl pyrazole-2-carboxylic acid.
Kibdelomycin Has Broad-Spectrum Gram-Positive
Activity
Kibdelomycin exhibited strong antibacterial activity against
wild-type S. aureus strains and showed a minimum inhibitory
concentration (MIC) value of 2 mg/ml (Table 2). It showed strong
activity against methicillin-resistant S. aureus (MRSA) with a
MIC of 0.5 mg/ml. Kibdelomycin inhibited growth of other key5–965, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 957
Figure 2. Chemical Structure of Kibdelomycin
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Enterococcus faecalis, with MIC values of 1 and 2 mg/ml, respec-
tively. It also inhibited the growth of a gram-negative pathogen,
Haemophilus influenzae, with a MIC value of 2 mg/ml. It did not
exhibit activity against other serious gram-negative wild-type
pathogens such as Escherichia coli (MIC >64 mg/ml). It did,
however, inhibit the growth of a permeable and efflux pump
mutant E. coli (envA1, tolC) strain with a MIC value of 32 mg/ml.
The activity of kibdelomycin was significantly reduced (MIC
64 mg/ml) when tested in the presence of 50% human serum.
Overall, the activity of kibdelomycin was similar to that of
novobiocin. Kibdelomycin did not inhibit the growth of Candida
albicans at 64 mg/ml.
AISS Profiling of Kibdelomycin
Kibdelomycin was subjected to the S. aureus fitness test to
confirm that it was the active component responsible for the
coumarin-like AISS profile of the crude extract. The profile
generated by kibdelomycin was highly correlated to the profiles
from the crude extract and novobiocin (Figure 1), with strong
depletions in the parE-AS and parC-AS strains (the two subunits
of topoIV) and the gyrB-AS strain (GyrB subunit of DNA gyrase)
along with shared depletions in the hu-AS (DNA binding protein),
alr-AS, and mfd-AS strains. Some of the secondary depletions
(mfd-AS, alr-AS, and hu-AS) were not as significant for kibdelo-
mycin as they were for novobiocin at all concentrations tested.
The most interesting difference between the two AISS profiles
was the strong depletions in gyrA-AS (GyrA subunit of DNA958 Chemistry & Biology 18, 955–965, August 26, 2011 ª2011 Elsevigyrase) in the novobiocin profiles and a lack of significant
gyrA-AS depletions for kibdelomycin.
The coumarin antibiotics, novobiocin and coumermycin A1,
inhibit the catalytic activity of DNA gyrase and topoIV through
inhibition of the ATPase activity of these heterodimeric type II
topoisomerases (reviewed: Maxwell and Lawson, 2003; Oblak
et al., 2007) leading to inhibition of DNA synthesis and cell death.
This differs from the MOA of the fluoroquinolone antibiotics that
form a drug-topoisomerase-DNA complex, which traps the
covalent intermediate of cleaved DNA to the GyrA or ParC
subunit (the cleavable complex), leading to DNA double-strand
break-induced cell death (Chen et al., 1996). These mechanistic
differences are reflected in the AISS profiles of these classes of
compounds (Donald et al., 2009) and suggest that kibdelomycin
is likely working through an MOA similar to that of the coumarin
antibiotics that involves inhibition of the ATPase activity of DNA
gyrase and topoIV (Figure 1).
Kibdelomycin Is a Selective Inhibitor of DNA Synthesis
and a Potent Inhibitor of Type II Bacterial
Topoisomerases
The macromolecular synthesis assay, in which the inhibition of
the intracellular building blocks of macromolecules are mea-
sured, provides guidance for understanding the broad MOA of
compounds (Wang et al., 2006). In this assay, as predicted by
the S. aureus fitness test, kibdelomycin inhibited DNA synthesis
(IC50 0.03 mg/ml) in S. aureus and showed more than 100-fold
selectivity over RNA, peptidoglycan, phospholipids, and protein
synthesis (Figure 3).
In the cell-free topoisomerase supercoiling and decatenation
assays, which measure the inhibitory effect of compounds on
the DNA supercoiling activity of the protein complexes of DNA
gyrase and the decatenation activity of DNA topoIV, kibdelomy-
cin inhibited E. coli gyrase supercoiling and topoIV decatenation
activity with IC50 values of 60 and 29,000 nM, respectively
(Table 3). It showedmore potent activity againstS. aureus gyrase
supercoiling (IC50 = 9 nM) with a 55-fold reduced potency
against S. aureus topoIV decatenation activity (IC50 = 500 nM)
(Table 3). In the catalytic ATPase assays, which measure the
inhibition of the holoenzyme ATPase activity, kibdelomycin
inhibited E. coli DNA gyrase ATPase activity with IC50 values of
11 nM and topoIV ATPase activity with an IC50 value of 900 nM
(Table 3). Similar to novobiocin, kibdelomycin was amore potent
inhibitor of E. coli DNA gyrase ATPase activity than it was an
inhibitor of topoIV ATPase activity.
The gyrase and topoIV activity profiles of kibdelomycin were
generally similar to novobiocin but showed significantly better
potency against S. aureus topoIV decatenation activity. These
results support the S. aureus fitness test prediction that kibdelo-
mycinworks through amechanism similar to that of the coumarin
antibiotic novobiocin that involves inhibition of the ATPase
activity of bacterial type II DNA topoisomerases, leading to inhi-
bition of DNA synthesis and cell death.
Kibdelomycin Is Not Cross-Resistant with Gyrase
Inhibitors
To test whether kibdelomycin acts at the same site as the
coumarin antibiotics, we selected strains resistant to novobiocin
or coumermycin A1. Strains MB 5957/A8 and MB 5957/H7 wereer Ltd All rights reserved
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2006) on Miller’s Luria agar plates containing 4x the agar dilution
MIC of novobiocin and coumermycin A1, respectively.
Kibdelomycin potently inhibited the growth of the wild-type
parent S. aureus strain with a MIC of 1 mg/ml. The activity of
kibdelomycin against MB 5957/A8 (novobiocin resistant) was
unaffected (MIC 0.5 mg/ml). Its activity against the S. aureus
strain harboring a 125-fold resistance to coumermycin A1 (MB
5957/H7) was reduced only four-fold relative to wild-type (Table
4). When tested against aS. aureus strain that harbors resistance
to the fluoroquinolone antibiotic ciprofloxacin (R35), kibdelomy-
cin’s activity was unaffected (MIC 0.5 mg/ml).
The gyrB gene was sequenced in strains MB 5957/A8 and MB
5957/H7 and the mutations found were Asp-89-Gly for A8
(novobiocin resistant isolate) and Gln-136-Glu, Ile-175-Thr,
and Leu-455-Ile for H7 (coumermycin A1 resistant isolate).
The crystal structure of Thermus thermophilus GyrB ATPase
domain in complex with novobiocin showed strong H-bond
interactions of Asp80 (Asp89 in S. aureus) with the p-hydroxy
group of the benzamide unit (Lamour et al., 2002) (Figure S3).
The loss of this interaction in the Asp89-Gly mutant (MB5957/
A8) would be sufficient to reduce the activity of novobiocin
and suggest that this interaction is unlikely to exist for
kibdelomycin.
S. aureus Has a Low Frequency of Resistance
to Kibdelomycin
The frequency of resistance (FOR) was measured at 2-, 4-, and
8-fold the drug concentrations of the agar plate MIC (Table
S1). The FOR was calculated by dividing the total number of
spontaneous resistant colonies found on the agar drug plates
after 24-hr incubation at 37C by the total number of colony-
forming units (cfu) spread on the drug plates. At 4- and 8-fold
concentrations of the plate MIC, the FOR of kibdelomycin
was <53 1010 cfu/ml. The FOR of novobiocin and ciprofloxacin
was measured simultaneously for comparison and is presented
in Table S1. Kibdelomycin displays a FOR similar to that of
ciprofloxacin.
DISCUSSION
Kibdelomycin is the first in a new class of natural-product bacte-
rial gyrase inhibitor to be discovered since the cyclothialidines
in the early 1990s (Oblak et al., 2007) and it is the first with potent
whole-cell antibacterial activity since the discovery of novobi-
ocin and the other coumarin antibiotics in the 1950s (Oblak
et al., 2007). The discovery demonstrates the advantages of
combining a high-throughput chemical genetic approach with
natural products screening for antibacterials. In nearly three
years of running the S. aureus fitness test natural products
screening paradigm, we re-discovered natural-product antibac-
terials targeting virtually every known major MOA along with
dozens of instances of the coumarin antibiotics novobiocin,
chlorobiocin, and coumermycin A1 (not shown). Because the
AISS profiling of the crude extract identified the likely MOA of
the active agent as being inhibition of DNA gyrase, we were
able to quickly rule out known inhibitors and confidently pursue
chemical isolation/purification of a new type II DNA topoisomer-
ase inhibitor. Although discoveries like that of the anti-fungalChemistry & Biology 18, 95parnafungin highlight the power of the fitness test approach for
finding compounds with novel MOAs (Jiang et al., 2008; Parish
et al., 2008), the discovery of kibdelomycin with the S. aureus
fitness test demonstrates the other strength of this unbiased
screening method, namely the ability to triage rapidly through
large numbers of biologically active crude extracts and identify
those containing new chemistries against proven therapeutic
targets.
Kibdelomycin is a potent and selective inhibitor of DNA
synthesis in which it blocks incorporation of 14C-thymidine.
The inhibition of DNA synthesis is the result of selective inhibition
of the ATPase activity of DNA gyrase and topoIV. Kibdelomycin
inhibited the in vitro DNA gyrase and topoIV activities of both
E. coli and S. aureus. The activity profile was similar to that of
the coumarin antibiotic novobiocin and not quinolone antibiotics.
In general, it showed much better potency against DNA gyrase
than DNA topoIV for both S. aureus– and E. coli–derived
enzymes. The inhibition of bacterial DNA synthesis leads to
potent antibacterial activity. Although it showed broad-spectrum
activity against gram-positive bacteria, its activity against wild-
type, gram-negative bacteria was limited to te respiratory
tract–infecting bacterium H. influenzae. The lack of activity
against most wild-type gram-negative bacteria such as E. coli
was attributed to either poor cell penetration or active efflux,
which was validated by its activity against the permeable
(envA1) and efflux (tolC) defective E. coli strain. Moreover, it
inhibited the in vitro DNA gyrase and topoIV activity of gram-
negative bacteria (e.g., E. coli), suggesting that wild-type activity
against Gram-negative bacteria is achievable by improving cell
permeation and/or reducing efflux activity of kibdelomycin
analogs. Remarkably, in these initial studies, kibdelomycin did
not show cross-resistance to known bacterial type II topoiso-
merase inhibitors (novobiocin, ciprofloxacin) regardless of
whether they interact with GyrB and ParE (coumarins) or GyrA
and ParC (quinolones) indicating a unique binding mode of this
compound to DNA gyrase and topoIV. Kibdelomycin showed
very low frequency of resistance (<5 3 1010), unlike other
known GyrB inhibitors (e. g., novobiocin, 108) (Young, 2006),
providing additional evidence for binding that is likely signifi-
cantly different from that of known GyrB inhibitors. Future
cross-resistance and mutation studies against a broader spec-
trum of resistant mutants and pathogenic organisms will be
necessary to ultimately explore potential mechanisms of resis-
tance to kibdelomycin.
The structure of kibdelomycin is completely novel compared
with the known GyrB and ParE inhibitors novobiocin, chlorobio-
cin, and coumermycin A1, which are natural products produced
by soil bacteria and were discovered in the 1950s (Oblak et al.,
2007). A related compound of unpublished activity, amycolami-
cin, was recently reported (Tohyama et al., 2010). Novobiocin
was one of the first gyrase inhibitors discovered and consists
of three domains: a central 8-methyl coumarin domain con-
nected with an amide bond to an isoprenyl hydroxy benzoic
acid on one side, and a carbamoyl-methyl-lyxofuranoside (novo-
biose) on the other. The methyl group of the coumarin and the
carbamoyl group of novobiose is substituted by a chloro and a
5-methyl-pyrole-2-carbonyl group in chlorobiocin. The third
inhibitor, coumermycin A1 is more complex and is a dimer con-
sisting of a 3-methyl-pyrrolyl-2,4-dicarbonyl as a central core5–965, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 959
Table 1. 1H (600 MHz) and 13C NMR (150 MHz) Spectral Assignment of Kibdelomycin in CD3OD
Atom #
Kibdelomycin
dC Type dH HMBC (H/C) ROESY
b
1 152.2 C
2 35.6 CH2 2.26, m (eq) —
2.12, m (ax) C-1, 3
3 35.3 CH2 2.25, m (eq) H-4, 30
1.26, m (ax)
4 79.6 CH 3.56, dt, 4, 11 C-5, 6, 30 H-10, 30
5 49.9 CH 1.82, dt, 2.5, 11 H-3ax, 6, 8
6 126.5 CH 5.92, dt, 10, 2 C-4, 5, 8, 10 H-4, 5, 7
7 133.7 CH 5.62, ddd, 10, 4.5, 3 H-8, 21
8 32.1 CH 2.65, m H-7, 21
9 48.0a CH 4.33, m C-5, 8, 10, 11, 21 H-5
10 39.5 CH 2.26, m C-1, 2, 4, 5, 8, 9, 20 H-2ax, 4, 21
11 198.0a C
12 105.2a C
13 196.6a C
14 69.7a br CH 3.52, d, 2.5 C-17, 18, 19, 16 H-17, 18, 19, 22
16 178.1a
17 32.0a CH 2.14, m C-13, 14, 18, 19 H-17, 18, 19
18 17.8 CH3 0.97, d, 7 C-14, 17, 19 H-14, 17, 19
19 17.7 CH3 1.07, d, 7 C-14, 17, 18 H-14, 17, 18
20 106.1 CH2 4.57, s C-1, 2, 10 H-2eq
4.44, s C-1, 2, 10
20 — N
21 18.9 CH3 0.80, d, 7 C-7, 8, 9 H-7, 8, 10
22 — O
22 77.5a CH 5.02, brd, 9 C-22, 23 H-14(w), 28
23 75.6 CH 4.33, m C-22, 24, 1% H-24, 25
24 69.9 CH 5.88, t, 3 C-22, 23, 25, 26, C-1’’ H-23, 25, 1%
25 69.8 CH 4.91, dd, 6, 3 C-24, 26, 28, C-10 H-23, 24, 26
26 71.4 CH 4.30, pent, 7 C-22, 25, 28 H-25
28 14.5 CH3 1.39, d, 7 C-25, 26 H-22, 26
29 — O
30 96.8 CH 4.94, dd, 10, 2 C-4, 34 H-4, 3eq, 34
31 38.5 CH2 1.79, dd, 13.5, 2 (eq) C-30, 32, 33, 37 H-38
1.57, dd, 13.5, 10 (ax) C-30
32 76.4 C
33 74.9 CH 3.17, d, 9 C-32, 34, 36, 37 H-36, 37
34 71.7 CH 3.67, dq, 9, 6 C-30, 33, 36 H-30, 36
36 18.5 CH3 1.26, d, 6 C-33, 34 H-33, 34
37 52.4 CH 4.37, q, 7 C-31, 32, 33, 38, 40 H-31ax, 33, 38
38 16.2 CH3 1.24, d, 7 C-32, 37 H-31ax, H-37
39 — NH
40 161.7 C
41 120.0 C
42 112.4 C
43 110.6 C
44 129.4 C
45 — NH
46 10.8 CH3 2.21, s C-41(w), 42(w), 43, 44
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Table 1. Continued
Atom #
Kibdelomycin
dC Type dH HMBC (H/C) ROESY
b
10 158.4 C
20 – NH2
1’’ 172.0 C
2’’ 21.0 CH3 2.11, s C-1’’
1’’ 57.5 CH3 3.28, s C-23 H-23, 24
W, weak; eq, equatorial; ax, axial. C-11 shift suggests a keto form. A multi-keto-enol form is possible, including involvement of imino group. See also
Figures S1 and S2.
aBroad signals.
bMix 200 and 300 ms.
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replacement of carbamoyl group with 5-methyl-2-pyrrolylcar-
bonyl group.
It has been shown in the co-crystal structure complex of
N-terminal domain of E. coli gyrase B24-novobiocin (PDB:
1AJ6) and gyrase B24-chlorobiocin (PDB: 1kzn) that the ATP
binding site overlaps with novobiocin and chlorobiocin binding
sites (Maxwell and Lawson, 2003; Tsai et al., 1997). Because
kibdelomycin inhibits gyrase B ATPase activity, it may bind at
the gyrase B catalytic site with similar interactions of 3,4-
dichloro-5-methyl-pyrrole to chlorobiocin’s methyl pyrrole but
with additional completely different interactions with the
remainder of the molecule.
Further work, including chemical modification, will be neces-
sary to determine whether kibdelomycin can be developed into
a therapeutic agent, but the discovery of this unique scaffold
from nature will at the very least add valuable insight into new
ways to chemically inhibit this extremely important antibacterial
drug target. This informationmaywell open the door to designing
new synthetic inhibitors and possibly engineering parts of the
kibdelomycin biosynthetic pathway to generate additional
important new classes of DNA gyrase inhibitors.Table 2. In Vitro Antimicrobial Activity (Minimum Inhibitory Concen
Novobiocin and Ciprofloxacin
Species Straina Kibde
S. aureus (MSSA) MB 2865 2
S. aureus (MSSA) MB 2865b 64
S. aureus (MRSA-COL) MB5393 0.5
S. pneumoniae CL2883c 1
E. faecalis CL8516 2
B. subtilis MB964 0.12
H. influenzae MB4572 2
E. coli MB2884 >64
E. coli (envA1, tolC) MB5746 32
C. albicans MY1055d >64
aActivities were assayed in cation adjusted Meuller Hinton Broth (CAMHB)
bCAMHB + 50% human serum.
cCAMHB + 2.5% lysed horse blood.
d YPD and Sab-Dex media.
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The emergence of resistant strains of bacteria has led to an
urgent need for new antibacterial agents. Burdened by the
re-discovery of thousands of known inhibitors what was
once one of themost successful paradigms for new antibac-
terial discovery, empiric screening of crude natural product
extracts against pathogenic bacteria has become increas-
ingly difficult in recent years. Here, with the discovery of
kibdelomycin, we demonstrate how applying a chemical
genetic approach in thepathogenicbacteriaStaphylococcus
aureus for mechanistic profiling of crude natural product
extracts can help overcome this obstacle to discover a new
chemical scaffold from nature against a clinically important
drug target. Using biochemical and microbiological assays
we show that kibdelomycin is a potent inhibitor of bacterial
type II topoisomerases (DNA gyrase and topoisomerase IV)
and that thismechanism leads to inhibition of DNA synthesis
and broad-spectrum, gram-positive antibacterial activity.
Kibdelomycin is the first novel class of bacterial gyrase
inhibitors with both potent in vitro and whole-cell antibacte-
rial activity to be discovered from natural product sourcestration, mg/ml) of Kibdelomycin and Known DNA Gyrase Inhibitors
lomycin Novobiocin Ciprofloxacin
0.25 0.12
16 0.25
0.06 0.25
1 2
32 2
2 0.06
0.12 %0.015
>32 %0.015
2 %0.015
>32 >16
, except where noted.
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Figure 3. Inhibition of Macromolecular Synthesis of Kibdelomycin
Inhibitory effects across increasing concentrations were determined
by measuring incorporation of radiolabeled precursors of either DNA
(14C-thymidine), RNA (3H-uridine), phospholipid (2-3H-glycerol), protein
(3H-leucine), or cell wall (14C-glycine) in S. aureus strain EP167.
Table 3. Enzyme Inhibitory Activities of Kibdelomycin
Assay
Kibdelomycin
(IC50, nM)
Novobiocin
(IC50, nM)
E. coli gyrase (Gel) 60 500
E. coli topoIV (Gel) 29,000 10,000
S. aureus gyrase (Gel) 9 <4
S. aureus topoIV (Gel) 500 35,000
E. coli gyrase (ATPase) 11 23
E. coli topoIV (ATPase) 900 450
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Discovery of Kibdelomycinsince the 1950s. Because kibdelomycin represents a new
chemistry, with apparently a new binding mode, against
this proven target, it may help circumvent some of the issues
of resistance and toxicity of other classes like the coumarin
antibiotics. In fact, this new compound does not show
cross-resistance with other major classes of DNA gyrase
inhibitors and it displays a significantly lower frequency to
resistance than the coumarin antibiotic novobiocin. The
identification of kibdelomycin demonstrates the power of
applying new approaches to natural products discovery.
Successes like this have the potential to revitalize interest
in natural products-based antibacterial drug discovery.
EXPERIMENTAL PROCEDURES
Producing Organism Isolation and Characterization
The strain was isolated from a soil sample collected in the forest of Pama,
a zone of dense, humid vegetation in the plateau of Bangui, in Central African
Republic. This soil was suspended in sterile water and pretreated following the
method by Hayakawa et al. (Hayakawa et al., 1997) before being plated on
selective isolation media and incubated at 28C for at least 6 weeks. Strain
MA7385 (ATCC PTA-10354) was isolated from a NZ-amine–based agar
medium containing nalidixic acid (20 ug/ml) and the colony was purified on
yeast extract malt extract glucose medium (ISP2) and preserved as frozen
agar plugs in 10% glycerol.
Molecular Characterization of the Strain: 16S rDNA Sequencing
and Phylogenetic Analysis
The taxonomic position of the strain was determined by phylogenetic analysis
of the 16S rDNA sequence with sequences of validated species of the family
Pseudonocardiaceae. The phylogenetic analysis, based on the Neighbor-
Joining method using matrix pairwise comparisons of sequences corrected
with Jukes and Cantor algorithm (Jukes and Cantor, 1969; Saitou and
Nei, 1987), shows that the strain MA7385 is a new member of the genus
Kibdelosporangium, a taxonomic position highly supported by the bootstrap
analysis (96%) used as a measure of statistical confidence.
Fermentation Procedure
Fermentation of Kibdelosporangium sp. (MA7385) was accomplished by inoc-
ulating several agar plugs with mycelia into seed broth flasks (50 ml medium in962 Chemistry & Biology 18, 955–965, August 26, 2011 ª2011 Elsevi250ml baffled flask). The formulation for the seed broth is as follows (g/l, unless
specified): soluble starch (20.0), dextrose (10.0), NZ amine type E (5.0)[nitrogen
source, mixture of amino acids obtained from casein hydrolysates], beef
extract (3.0), peptone (5.0) [another nitrogen source, mixture of amino acids
obtained from meat].
Yeast extract (5.0), CaCO3 (1.0) in distilled H2O (1 l). The pH was adjusted to
7.0 with NaOH before addition of CaCO3. The flasks were incubated at 28
C
with 80% relative humidity and shaken on a rotary shaker at 220 rpm. When
the seed stage flasks had grown for 3 days, a 1 ml aliquot was used to inocu-
late each flask of FR23 production medium (50 ml medium in a 250 unbaffled
flask). The formulation of FR23 medium consists of (g/l): glucose (5.0), soluble
starch (30.0), cane molasses (20.0), and pharmamedia (20.0), in distilled H2O
(1 l). The pH was adjusted to 7.0 with NaOH before sterilization. The flasks
were incubated at 28C with 80% relative humidity on a rotary shaker at
220 rpm for 7 days.
Purification of Kibdelomycin
A pooled fermentation broth from 240 flasks (12 l) was extracted with 12 l
acetone by shaking on a reciprocating shaker for more than 1 hr. The mycelial
content was filtered through celite, and the filtrate was concentrated under
reduced pressure to remove most of the acetone. The aqueous extract (12 l)
was extracted three times with 12 l each of methyl ethyl ketone (MEK). MEK
extracts were combined and concentrated under reduced pressure to dryness
yielding a gum, which was dissolved in 20 ml of methanol and chromato-
graphed on a 450-cc Sephadex LH 20 column. The column was eluted with
methanol, and the appropriate fractions were pooled and concentrated under
reduced pressure to dryness. One-third portion of the LH20 fraction was dis-
solved in minimum volume of methanol and diluted with methylene chloride to
a ratio of 90:10, methylene chloride: methanol. This solution was then charged
to a 35 ml (10 g) silica gel column and washed with 3–4 column volumes each
of 10, 20, and 30%methanol in methylene chloride. The compound of interest
eluted in the 10%–20% methanol fraction. This process was repeated twice
with the rest of the material, and pooled fractions from the 3 columns were
concentrated under reduced pressure to yield a brown gum. This enriched
material was dissolved in 10 ml methanol and further fractionated into 5 equal
portions on PRP-1 (Hamilton’s pH stable high-performance liquid chromatog-
raphy [HPLC] column, 250 3 21.5 mm) using gradient elution with metha-
nol:0.25M sodium phosphate buffer (pH 7) 60:40 to 80:20 in 40 min at a flow
rate of 10 ml/min. Fractions of interest were dried down and repeatedly
triturated with methanol to dissolve all but the buffer salts. Another HPLC
step followed on Zorbax RX C8 (250 3 21.5 mm) eluted with a 50-min linear
gradient of 50%–100% aqueous methanol. Lyophilization of the fractions
containing compound afforded kibdelomycin (60mg, isolated yield 5mg/l, titer
in the extract = 10 mg/l) from fractions 41–44, as a colorless amorphous
powder. Physical and spectral properties of kibdelomycin: [a]23D = 43.6
(c, 1.56 MeOH); UV (MeOH) lmax (log ε) = 248 nm (sh) and 276 nm (4.42);
IR (ZnSe) nmax = 3417, 2932, 1732, 1611, 1537, 1454, 1376, 1313, 1233,
1159, 1079, 1004, 893, 830, 789, 745 cm-1. HRESIFTMS (m/z): observed for
M+H = 939.3562, calculated for C44H60Cl2N4O14
+H = 939.3561.
S. aureus Fitness Test
The S. aureus fitness test assay was performed as previously described (Don-
ald et al., 2009). Briefly, 245 strains, each containing a different inducible
antisense RNA interference plasmid targeting an essential gene in S. aureuser Ltd All rights reserved
Table 4. In Vitro Antimicrobial Activity of Kibdelomycin against Resistant Strains of Novobiocin, Coumermycin A1, and Ciprofloxacin
Species Straina Genotype Kibdelomycin Novobiocin Coumermycin A1 Ciprofloxacin
S. aureus wild-type Parent MB 5957 Wild-type 1 0.5 0.008 1
S. aureus NovoR MB 5957/A8 GyrB (ASP89Gly) 0.5 4 0.004 0.25
S. aureus CouR MB 5957/H7 GyrB (Gln136Glu,
Ile175Thr, Leu455Ile)
4 0.25 >1 0.12
S. aureus CiproS MB 5785 (R34) Parent for R35 1 0.5 0.004 0.5
S. aureus CiproR MB 5786 (R35) Unknown 0.5 0.25 0.004 >16
See also Figure S3.
a Activities were assayed in Miller’s Luria broth. MRSA strain R35 is a fluoroquinolone-resistant derivative of strain R34 (Hooper and Wolfson, unpub-
lished data).
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Discovery of KibdelomycinRN4220 were pooled into 24 different bins of 6–12 strains each. The bins were
then each grown at a different concentration of xylose inducer (ranging from
1.8–55 mM) for 20 population doublings either in the presence of test
compound (acetone extract or purified compound) or as a 2% DMSO mock
treatment control. Strain bin growth was performed in 384-well plates (Costar
3680) on a fully automated system using LBmedium containing chloramphen-
icol (34 mg/ml) over 3 cycles of growth ranging from 5–7 hr each for a total time
of18 hr in a total volume of 50 ml. At the end of the growth period, cells from all
24 bins were pooled for each test treatment or DMSOmock treatment control.
Pooled cells were then lysed and subjected to multiplex PCR to amplify
specific antisensemarkers for each strain. Strain specificmarkers were subse-
quently identified and peak areas quantitated by DNA fragment analysis on an
ABI 3730 genetic analyzer. Peak areas were then normalized and strain deple-
tion ratios were calculated. Statistical significance was determined as a p-
value using an error model generated for each individual strain across
a discrete set of known standards and unknown test samples selected to
represent total coverage of all strains within the array set.
Inhibition of Macromolecular Synthesis
The assay was performed as previously described (Wang et al., 2003; Wang
et al., 2006). Briefly, mid-log (A600 = 0.5–0.6) S. aureus growth was incubated
with increasing concentration of inhibitor at 37C for 20 min with 1 mCi/ml
2-[3H]-glycerol, 1 mCi/ml [14C]-thymidine, 1 mCi/ml [3H]-uridine, 5 mCi/ml
4,5-[3H]-leucine, or [14C]-glycine to measure phospholipids, DNA, RNA,
protein, and cell wall synthesis, respectively. Cell wall labeling with
[14C]-glycine (S. aureus) was performed in the presence of 100 mg/ml chloram-
phenicol, which prevents protein synthesis and disengages the stringent
response. The reaction was stopped by the addition of 10% trichloroacetic
acid and the cells were harvested using a glass fiber filter (PerkinElmer Life
Sciences, Waltham, MA, 1205-401). The filter was dried and counted with
scintillation fluid.
Bacterial DNA Gyrase Supercoiling and Topoisomerase
Decatenation Inhibition Assays
DNA gyrase and topoIV assays were performed based on established proto-
cols obtained from the supplier, TopoGEN, Inc. (Port Orange, FL). All of the
reactions were stopped by the addition of 10 ml of 3X gel-loading buffer (final
concentration: 1.2% SDS, 6 mM EDTA, 10% glycerol, 0.02% bromophenol
blue). Twenty ml of this was loaded on a 1% agarose, TAE (40mMTris-acetate,
0.01 M EDTA pH 8.3) gel and run for 3–4 hr at 60 V. The gel was stained with
0.5 mg/l ethidium bromide in TAE for 30 min while rocking, then destained for
20 min in deionized water. Fluorescent images were captured on a UV trans-
illuminator imaging system at a wavelength of 300 nm (Epichemi3, UVP Inc.
Upland, CA, uvp@uvp.com). The fluorescence intensity of the supercoiled
plasmid reaction product, in the case of gyrase, and the decatenation product
of topoisomerase were quantitated using ImagQuant software (GEHealthcare,
Little Chalfont, UK) and IC50 values were determined by non-linear regression
analysis in GraphPad Prism (GraphPad Software, Inc., San Diego, CA).
Supercoiling of relaxed plasmid DNA (pBR322 from TopoGEN) was assayed
in a reaction volume of 20 ml composed of 35 mM Tris pH 7, 24 mM KCl, 4 mM
MgCl2, 2 mM DTT, 1.8 mM spermidine, 6.5% glycerol, 0.1 mg/ml acetylated
BSA, 1 mM ATP, and 0.2 mg pBR322 substrate. Compound titrations inChemistry & Biology 18, 95DMSO were added and the reactions were initiated with 2 units of E. coli
gyrase (TopoGEN). The reaction proceeded with shaking on a mini-orbital
shaker (Bellco Biotechnology, Vineland, NJ) for 30 min at 37C. For the
S. aureusDNAgyrase assay, 5 units of enzyme (TopoGEN)were used in a reac-
tion mix that was supplemented with 0.6 M potassium glutamate.
Decatenation of kinetoplast DNA (TopoGEN) was assayed in a total reaction
volume of 20 ml containing 40 mM Tris pH 7.5, 6 mM MgCl2, 10 mM DTT,
100 mM potassium glutamate, 50 mg/ml acetylated BSA, 1 mM ATP, and
0.2 mg kDNA substrate. Compound titrations in DMSO were added and the
reactions were initiated with 2 units of E. coli topoIV (Topogen) that were incu-
bated with shaking for 30 min at 37C. For the S. aureus enzyme assay, 5 units
of S. aureus topoIV (TopoGEN) were used in a reaction that was supplemented
with 0.6 M potassium glutamate.
ATPase Assays and Data Analysis
The ATPase activity of E. coli gyrase and topoIV enzymes was measured with
a colorimetric assay for release of inorganic phosphate (Rivetna et al., 1995).
E. coli gyrase and topoIV holoenzymes, and kinetoplast DNA (kDNA) were
obtained from TopoGEN, Inc. The standard gyrase ATPase assay was
performed in a 96 well half area, clear, polystyrene microplate with 50 ul of
a reaction mix comprised of 100 mM Tris buffer (pH 7.4), 100 mM KCl, 5 mM
MgCl2, 200 mMATP, 15 mg/ml E. coli gyrase, and test compound. The standard
topoisomerase assay was run under equivalent conditions using 15 mg/ml
E. coli topoIV in the presence or absence of 19 mg/ml kinetoplast DNA. Back-
ground samples contained assay buffer in place of enzymes. Samples were
incubated at room temperature for 1 hr before terminating the reaction by
the addition of 25 ml 0.016% malachite green/0.4% polyvinyl alcohol and
mixing. Color determination was achieved with the addition of 25 ml 0.04M
molybdate/2N H2SO4 and the samples were again mixed very well. The
samples were incubated for 30 min at room temperature and the absorbance
at 620 nmwas read in aMolecular Devices SpectraMax Plus plate reader (Sun-
nyvale, CA). Background valueswere subtracted from all data points, inhibition
curves were plotted, and IC50 values were calculated with a 4-parameter fit
using KaleidaGraph (Synergy Software).
Microbiological Assays
The MIC against each of the strains was determined using Clinical and
Laboratory Standards Institute guidelines. The specified medium broth with
a 2-serial dilution of compounds was inoculated with 105 cfu/ml and was incu-
bated at 37C for 20 hr. MIC is defined as the lowest concentration of antibiotic
that inhibited visible growth.
Agar Dilution MIC, FOR Determination, and Luria-Delbruck
Fluctuation Test
Test compounds were incorporated into a solid (LB-agar plate medium). The
compounds were diluted in agar at 2-fold serial dilution. A defined number
of cells from a late log-phase liquid culture ofS. aureus grown in LB broth liquid
culture were spotted onto the surface of the agar drug medium. The number of
cells on the surface of drug agar medium was determined by the cell titer of
cells on agar medium without drug. Agar plates with and without drug were
incubated for 18 hr at 35C and then examined for growth. No growth of the
test organism on drug-containing plates indicates susceptibility at the5–965, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 963
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Discovery of Kibdelomycinantimicrobial concentration incorporated into the medium and this is referred
to as the agar plate MIC. The FOR was determined by plating late-log liquid
cultures of S. aureus onto plates containing 2X, 4X, and 8X the agar plate
MIC. The number of cells plated on all plates is determined by the cell titer
on the plates without drug.
Luria-Delbruck fluctuation tests were also performed for the control antibi-
otics novobiocin and coumermycin A1, essentially as described (Young,
2006) on Miller’s Luria agar plates containing 4X the agar dilution MIC of
novobiocin and coumermycin A1, respectively. Colonies from independent
plates were purified by streaking on plates without antibiotic. The resistance
was characterized by agar dilution MICs on agar plates containing various
antibiotics. MB5957/A8 was chosen for further study because of selective
resistance to novobiocin, whereas MB5957/H7 was chosen because of selec-
tive resistance to coumermycin A1.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and one table and can be
found with this article online at doi:10.1016/j.chembiol.2011.06.011.
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